Springfield City Group joins forces with UQ to improve health and wellbeing

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

As­traZeneca will pay $1 bil­lion to buy Chi­na-US cell ther­a­py com­pa­ny Gra­cell Biotech­nolo­gies, adding to a rush of deals that have been an­nounced at the

Trial findings revealed that the therapy effectively controlled symptoms such as runny nose and nasal itching. Credit: Pormezz/Shutterstock. China’s National Medical Products Administration (NMPA) has